AR082692A1 - Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit - Google Patents
Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kitInfo
- Publication number
- AR082692A1 AR082692A1 ARP110102962A ARP110102962A AR082692A1 AR 082692 A1 AR082692 A1 AR 082692A1 AR P110102962 A ARP110102962 A AR P110102962A AR P110102962 A ARP110102962 A AR P110102962A AR 082692 A1 AR082692 A1 AR 082692A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical product
- cancer
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 5
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 abstract 2
- 201000002510 thyroid cancer Diseases 0.000 abstract 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 2
- VLMVTMCKGVRPGT-UHFFFAOYSA-N (3-amino-2,6-difluorophenyl)-[5-(4-chlorophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]methanone Chemical compound NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F VLMVTMCKGVRPGT-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229960005395 cetuximab Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Terapia de combinación para tratar a un paciente que sufre de un trastorno proliferativo, de una forma particular, un tumor sólido, por ejemplo, un melanoma, un cáncer de tiroides y un cáncer colorrectal.Reivindicación 1: Un producto farmacéutico, el cual comprende, como un agente activo, (A) la {3-[5-(4-cloro-fenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico, o una sal de ésta, farmacéuticamente aceptable; y (B), un segundo componente, el cual comprende, como un ingrediente activo, un inhibidor de topoisomerasa; como una preparación combinada para el uso simultáneo o secuencial, en el tratamiento de un trastorno proliferativo, de una forma particular, un cáncer, de una forma más particular, un cáncer colorrectal, un melanoma y un cáncer de tiroides, que comprende una b-Raf que tiene una mutación V600. Reivindicación 3: El producto farmacéutico, según la reivindicación 1 ó 2, en donde, el citado inhibidor de topoisomerasa, es el irinotecan, o una sal de éste, farmacéuticamente aceptable. Reivindicación 5: El producto farmacéutico, según la reivindicación 4, en donde, el citado inhibidor de EGFR, es el cetuximab. Reivindicación 7: El producto farmacéutico, según una cualquiera de las reivindicaciones 1 a 6, que comprende {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico, o una sal de ésta, farmacéuticamente aceptable, contenida en un complejo molecular sólido, formado con acetato-succinato de hidroxipropilmetilcelulosa, de tal forma que, ésta, se encentra inmovilizada en su estado amorfo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37428810P | 2010-08-17 | 2010-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082692A1 true AR082692A1 (es) | 2012-12-26 |
Family
ID=44651664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102962A AR082692A1 (es) | 2010-08-17 | 2011-08-15 | Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120045433A1 (es) |
| EP (1) | EP2605766A2 (es) |
| JP (1) | JP2013538200A (es) |
| KR (1) | KR20130073948A (es) |
| CN (1) | CN103491952A (es) |
| AR (1) | AR082692A1 (es) |
| AU (1) | AU2011290857A1 (es) |
| CA (1) | CA2807218A1 (es) |
| MX (1) | MX2013001531A (es) |
| SG (1) | SG187828A1 (es) |
| TW (1) | TW201213326A (es) |
| WO (1) | WO2012022677A2 (es) |
| ZA (1) | ZA201300762B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| EP3574904A1 (en) | 2012-08-07 | 2019-12-04 | Array Biopharma, Inc. | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| PT2884979T (pt) | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| CN116333154A (zh) * | 2019-08-19 | 2023-06-27 | 美勒斯公司 | 用结合lgr5和egfr的抗体与拓扑异构酶i抑制剂的组合治疗癌症 |
| KR20230127007A (ko) * | 2022-02-24 | 2023-08-31 | 한국생명공학연구원 | Ednra 억제제를 유효성분으로 포함하는 대장암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1251850E (pt) * | 2000-01-26 | 2006-10-31 | Schering Corp | Utilizacao de uma preparacao de combinacao na terapia do cancro |
| US6545010B2 (en) * | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| DE60118547T2 (de) * | 2000-05-15 | 2007-02-01 | Celgene Corp. | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält |
| AU2002211725B2 (en) * | 2000-10-13 | 2005-06-30 | Vion Pharmaceuticals, Inc. | Modified prodrug forms of AP/AMP |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| JP2008535508A (ja) * | 2005-04-14 | 2008-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法 |
| US20070059310A1 (en) * | 2005-05-03 | 2007-03-15 | Karel Steven J | Therapeutic combination compositions and methods of using same |
| US20060257400A1 (en) * | 2005-05-13 | 2006-11-16 | Bristol-Myers Squibb Company | Combination therapy |
| PL1893612T3 (pl) * | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| WO2007128557A1 (en) * | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| MX2009002936A (es) * | 2006-09-19 | 2009-04-01 | Novartis Ag | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. |
| WO2008111441A1 (ja) * | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
| EP2821488B1 (en) * | 2007-08-01 | 2016-07-27 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of TLR9 |
-
2011
- 2011-08-10 US US13/206,548 patent/US20120045433A1/en not_active Abandoned
- 2011-08-12 KR KR1020137006538A patent/KR20130073948A/ko not_active Withdrawn
- 2011-08-12 CN CN201180050099.0A patent/CN103491952A/zh not_active Withdrawn
- 2011-08-12 AU AU2011290857A patent/AU2011290857A1/en not_active Withdrawn
- 2011-08-12 MX MX2013001531A patent/MX2013001531A/es not_active Application Discontinuation
- 2011-08-12 CA CA2807218A patent/CA2807218A1/en not_active Withdrawn
- 2011-08-12 WO PCT/EP2011/063892 patent/WO2012022677A2/en not_active Ceased
- 2011-08-12 EP EP11757192.7A patent/EP2605766A2/en not_active Withdrawn
- 2011-08-12 JP JP2013524420A patent/JP2013538200A/ja not_active Withdrawn
- 2011-08-12 SG SG2013010657A patent/SG187828A1/en unknown
- 2011-08-15 AR ARP110102962A patent/AR082692A1/es unknown
- 2011-08-15 TW TW100129118A patent/TW201213326A/zh unknown
-
2013
- 2013-01-29 ZA ZA2013/00762A patent/ZA201300762B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2605766A2 (en) | 2013-06-26 |
| SG187828A1 (en) | 2013-03-28 |
| TW201213326A (en) | 2012-04-01 |
| CA2807218A1 (en) | 2012-02-23 |
| JP2013538200A (ja) | 2013-10-10 |
| WO2012022677A2 (en) | 2012-02-23 |
| US20120045433A1 (en) | 2012-02-23 |
| MX2013001531A (es) | 2013-03-18 |
| CN103491952A (zh) | 2014-01-01 |
| KR20130073948A (ko) | 2013-07-03 |
| WO2012022677A3 (en) | 2013-07-25 |
| AU2011290857A1 (en) | 2013-01-31 |
| ZA201300762B (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082692A1 (es) | Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| MX2019013643A (es) | Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. | |
| WO2013059737A3 (en) | Tissue treatment device and related methods | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| WO2009126931A3 (en) | Therapy for bipolar disorder and mania with buprenorphine | |
| BR112014018910A8 (pt) | Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores | |
| BR112013011480A8 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| HK1215253A1 (zh) | 作为激酶抑制剂的吡咯并嘧啶化合物 | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| EA201590870A1 (ru) | АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ | |
| MX346455B (es) | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica. | |
| HK1203489A1 (en) | Purinone compounds as kinase inhibitors | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| FI2694072T4 (fi) | Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa | |
| CA2875824C (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| WO2009143156A3 (en) | Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| CL2013002005A1 (es) | Compuesto 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2s)-2-metoxipropil]-3-metil-1,3-dihidro-2h-imidazo[4,5-c]quinazolin-2-ona; inhibidor pi3k y como mtor; composicion farmaceutica que lo comprende; combinacion farmceutica; y su uso en el tratamiento del cancer. | |
| EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| HK1198279A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |